<DOC>
	<DOCNO>NCT01190475</DOCNO>
	<brief_summary>This study ass safety tolerability BGS649 woman moderate severe endometriosis .</brief_summary>
	<brief_title>BGS649 Monotherapy Moderate Severe Endometriosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Premenopausal woman document moderate severe endometriosis . Occurrence three sequential menstrual cycle 2435 day duration prior enrollment . Laparoscopically proven diagnosis moderate severe endometriosis ( diagnose within past 10 year screen ) . Patients plan become pregnant within one year screen visit willing use two effective method nonhormonal , barrier birth control duration study surgically sterile . Patients must score least 4 numerical rating scale ( NRS ) one follow three pain measurement : pelvic pain , menstrual pain dyspareunia Estrogen replacement therapy use either prescription medication estrogencontaining OTC nutritional/herbal supplement soy extract topical estrogen . Aromatase inhibitor therapy ( include Femara ( letrozole ) , Aromasin ( exemestane ) Arimidex ( anastrozole ) within past 12 month . Oral bisphosphonate therapy ( i.e . Fosamax ( alendronate ) ) within past 6 month intravenous bisphosphonate ( i.e. , Reclast , pamidronate ) &lt; 15 month screen . Systemic glucocorticoid therapy within past 4 week . Contraindications oral contraceptive use . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>Infertility</keyword>
	<keyword>Pain</keyword>
	<keyword>Vaginal Diseases</keyword>
	<keyword>Uterine Diseases</keyword>
</DOC>